

UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Meeting Minutes

Meeting Date: September 14, 2017

Location: Via conference call/WebEx

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order	G. Shutzberg	5:06 PM EST		
A. Minutes of previous meetings	G. Shutzberg	Review of Minutes from June 15, 2017	Minutes reviewed, approved	Yes
B. Formulary Review - New Drugs	G. Shutzberg	Austedo (deutetrabenazine) tablets		
		Recommendation: • Preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	K. Slanina	Ingrezza (valbenazine) capsules		
		Recommendation: • Non-preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	G. Shutzberg	Zejula (niraparib) capsules		
		Recommendation: • Preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	G. Shutzberg	Alunbrig (brigatinib) tablets		
		Recommendation: • Preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	K. Slanina	Rydapt (midostaurin) capsules		
		Recommendation: • Preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	K. Slanina	Kevzara (sarilumab) injection		
		Recommendation: • Non-preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	G. Shutzberg	Brineura (cerliponase alfa) injection		
		• Confirm Review of Medical Benefit	no vote. Medical Benefit Review	Yes
	K. Slanina	Imfinzi (durvalumab) injection		
		• Confirm Review of Medical Benefit	no vote. Medical Benefit Review	Yes
B. Formulary Review - Class Review	G. Shutzberg	MAO-B Inhibitors for Parkinson's Disease		
		Confirm class review	Yes/No	Yes
		Recommendation: • Xadago: Non-preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Selegiline capsules: Move to preferred across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	K. Slanina	Hepatitis C Agents		
		Confirm class review	Yes/No	Yes
		Recommendation: • Mavyret: Preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Vosevi: Non-preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Epclusa: Move to non-preferred with prior authorization across all lines of business. Grandfather current utilizers through completion of regimen.	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Sovaldi: Move to non-preferred with prior authorization across all lines of business. Grandfather current utilizers through completion of regimen.	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Zepatier: Move to non-preferred with prior authorization across all lines of business. Grandfather current utilizers through completion of regimen.	Motion made, seconded, and carried to accept recommendation	10:0
	Comments:	• Marcia Cort questioned if there will be additional items needed on the prior authorization form for drugs other than Mavyret? • Alex Hindman responded that Mavyret will cover most hepatitis C patients, but if a patient cannot take Mavyret due to a contraindication, the prescriber can provide rationale as to why the patient needs an alternative treatment and the requested medication will be approved. Kelsey Slanina gave an example: Mavyret is contraindicated in patients with decompensated cirrhosis. If the prescriber is requesting a drug other than Mavyret and indicates their patient has decompensated cirrhosis, the requested medication would be approved.		
	G. Shutzberg	PD-1/PD-L1 Inhibitors		
		Confirm class review	Yes/No	Yes
		• Confirm Review of Medical Benefit	no vote. Medical Benefit Review	Yes

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
B. Formulary Review - PDL Modifications	A. Hindman	SGLT2		
		Recommendation contingent on Drug Designation changing: • Jardiance: Move to non-preferred with prior authorization across all lines of business. Transition current users to Invokana or Invokamet.	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation contingent on Drug Designation changing: • Synjardy: Move to non-preferred with prior authorization across all lines of business. Transition current users to Invokana or Invokamet.	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation contingent on Drug Designation changing: • Synjardy XR: Move to non-preferred with prior authorization across all lines of business. Transition current users to Invokana or Invokamet.	Motion made, seconded, and carried to accept recommendation	10:0
	Comments:	• Marcia Cort questioned if the ask was to confirm the review or if a vote was needed for these recommendations. • Alex Hindman responded that this is a voting item and clarified that we are recommending to move Jardiance, Synjardy and Synjardy XR to non-preferred.		
	A. Hindman	Otezla		
		Recommendation: • Move to preferred with prior authorization across all lines of business.	Motion made, seconded, and carried to accept recommendation	10:0
		Atopic Dermatitis		
		Recommendation: • Eucrisa: Move to preferred with a double step through a topical corticosteroid and a topical calcineurin inhibitor (Elidel, Protopic)	Motion made, seconded, and carried to accept recommendation	10:0
		Descovy (emtricitabine/tenofovir alafenamide) tablet		
		Recommendation: • Move to preferred across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Fluticasone / Salmeterol Inhaler (Authorized Generic for AirDuo)		
		Recommendation: • Remove the Step Therapy requirement.	Motion made, seconded, and carried to accept recommendation	10:0
		Pyrimethamine 50mg / Leucovorin calcium 20mg		
		Recommendation: • Move to preferred across all lines of business. Add the bulk ingredients to the PDL and allow the ingredients to be compounded as an alternative to Daraprim.	Motion made, seconded, and carried to accept recommendation	10:0
B. Formulary Review - Re-Classifications	G. Shutzberg	Amyotrophic Lateral Sclerosis (ALS) Agents		
		Recommendation: • Rilutek: Move to preferred across all lines of business.	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Radicava: Confirm review of medical benefit	no vote. Medical Benefit Review	Yes
	G. Shutzberg	Long-Acting Insulin Analogs		
		Recommendation: • No changes recommended	Motion made, seconded, and carried to accept recommendation	10:0
B. Formulary Review - New Formulations	G. Shutzberg	Confirm review of grid	Yes/No	Yes
	G. Shutzberg	Isentress HD (raltegravir) tablets		
		Recommendation: • Preferred across all lines of business.	Motion made, seconded, and carried to accept recommendation	10:0
	G. Shutzberg	Selzentry (maraviroc) oral solution; 25mg and 75mg tablets		
		Recommendation: • Preferred across all lines of business.	Motion made, seconded, and carried to accept recommendation	Yes
	G. Shutzberg	Motofen (difenoxylin/atropine) tablets		
		Recommendation: • Non-preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	G. Shutzberg	Rhofade (oxymetazoline) 1% cream		
		Recommendation: • Non-preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	G. Shutzberg	Rituxan Hycela (rituximab and hyaluronidase human)		
		Recommendation: • Confirm review of medical benefit	no vote. Medical Benefit Review	Yes
B. Formulary Review - Drugs Evaluated Per Grid	G. Shutzberg	Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	10:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
C. Clinical Guidelines	K. Slanina	Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	10:0
	K. Slanina	Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	10:0
	K. Slanina	Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	10:0
E. Quality Monitoring	L. Smith/K. Slanina	Confirm Review of Quality Data	Yes/No	Yes
	L. Smith	DUR Review		
	Comments:	<ul style="list-style-type: none"> Ana Fuentes commented that the LTC carriers seems to be out of the 10-15% range on the long acting Opioids outcomes data. Asked if the data for the AZ LTC can be shared. Leah Smith confirmed that she will follow-up with the AZ LTC data. Ana Fuentes asked if the opioid dashboard from OptumRx is posted for other health plan reviews? Leah Smith stated that she sends the data via email to the regional pharmacy team once it is available to her. Ana Fuentes asked if she could be added to the distribution list so she can distribute to the national team. 		
	K. Slanina	Top 25 Drugs by Cost and Volume – 2nd Quarter 2017		
	K. Slanina	Top 10 Drugs Requested - Approvals and Denials – 2nd Quarter 2017		
	K. Slanina	Grievances and Appeals Data – 2nd Quarter 2017		
	K. Slanina	Inter-Rater Reliability (IRR) – 3rd Quarter 2017 <ul style="list-style-type: none"> Pharmacists Medical Directors 		
Adjournment	G. Shutzberg		6:57 PM EST	

Votes not totaling 10 are the result of abstentions.

Respectfully Submitted to the Committee,



James P. Hancovsky, M.S.I.A., R.Ph.
Chief Pharmacy Officer of C&S